Cookies on the ehospice website

We use cookies to ensure that we give you the best experience on our website. We also use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on the ehospice website. However, if you would like to, you can change your cookie settings at any time.

Appeal to withdraw the ban on Dextropropoxyphene

Author: Nisha Krishnadas
16 June 2013

The ban on the pain relieving medicine, Dextropropoxyphene in India has elicited concern and protest from palliative care community in the country. Dextropropoxyphene- a 40 year old synthetic opioid analgesic- is widely used in palliative care and is easily available in India, even in remote villages. As it is an inexpensive and accessible medicine it helps hundreds of suffering patients in a country like India where stringent rules denies access to opioids including morphine.

Even though the government has announced the ban in the Gazette Notification dated 23rd May 2013, it came into effect in the country from 14th June 2013, after announcing it through news papers and other media.

As per the Gazette Notification, the government has suspended manufacture for sale, sale and distribution of Dextyropropoxyphene and formulations containing Detropropoxyphene as its use is likely to involve risks to human beings.

 Even if the gazette notification clarifies the ban is due to the harmful effects of the medicine, medical professionals believe that the government action is due to misuse of the drug by addicts. The sale of the drug showed a huge spurt in the north-east, pointing to the possibility of it being smuggled out of the country. The Press Trust of India reports that the drug was under the scanner of authorities for quite some time after it was banned in various countries like UK and US.

The evidence against the medicine are flimsy- said Dr. M. R. Rajagopal, Chairman, Pallium India( WHO Collaboration Centre for Training and Policy on Access to Pain Relief).

According to him evidence is usually in favor of expensive drugs because drug research is costly and  90% of drug research is funded by the Pharmaceutical industry which has little interest in inexpensive drugs.

"By banning the drug  in India, the axe is falling on the least expensive step II opioid, available for oral use. 100 mg of Tramadol four times a day would cost twice the daily income that defines the poverty line. Stringent narcotic regulations restrict the availability of oral morphine to a tiny fraction of the needy. What the average Indian could afford and could get is Dextropropoxyphene"- said Dr. Rajagopal.

The reasons cited  to withdraw Dextropropoxyphene in western countries were different . In Europe, UK and Sweden banned the drug on the argument that :
1. It is a major contributor to self harm

2. It is not an effective analgesic – Lack of additional efficacy over Paracetamol

"But both these arguments haven’t been proved with enough evidence and the situation in India is entirely different from these countries-" argues Dr. Suresh Kumar, Director, Institute of Palliative Medicine (WHO Collaboration Centre in Community Based Palliative Care and Long Term Care).

During 2001-2007, more than 17% of suicidal deaths due to poisoning in UK were documented to be due to Dextropropoxyphene.

“Not all European countries agreed with Sweden and UK on the toxicity of Dextroprpoxyphene, because the argument regarding suicides was not convincing enough due to variability in documentation of drug concentration in post-mortem studies. Follow up studies after the ban has shown that suicides by Dextroprpoxyphene came down after the ban (Obviously!), but these papers also show that there is no reduction in the incidence of suicide”- Dr. Suresh points out. He also explains that Dextropropxyphene has never been considered as an agent for suicide in India. The National Representative survey published last year clearly states Pesticides, hanging, drowning and burns as the major agents. The study published in Lancet last year does not even mention the drug.

According to Dr. Suresh, efficacy studies in pain relief can become meaningless in contexts other than the one in which the study was done. The study that showed lack of additional efficacy of Dextropropoxyphene over Paracetamol (published in BMJ) was a study of the effect on moderate pain, not severe pain like the one in cancer. There are similar studies showing the lack of efficacy of many other analgesics. See for example, the study from Norway which showed that 50 and 100mg Tramadol is only as good as placebo.

The reason for withdrawing the drug from US market was the Food and Drug Authority’s (FDA) recommendation based on the observation of prolonged QTC interval. “But QT prolongation has not been studied in the case of most of the analgesics currently in the market. See the available studies. ”- explained Dr. Suresh. There is evidence of accepted level of effect on the QT interval only in the case of methadone, oxycodone, and LAAM (levo–acetylmethadol).

"The reasons cited in the Government Gazette to ban the  drug is very vague and can be said about many medications. There are instances where medicines with potential risks are used when their potential benefits out weigh the risks. The fact remains that dextropropoxyphene is an useful analgesic-" said Dr. Anil Paleri, Hon. Secretary of Indian Association of palliative care. " If the Government is banning the drug to block the illegal trade I would say it is like 'burning the house down to kill the rat'!."

While raising their protests, medical professionals working in the field of palliative care in India has urged palliative care community to act on this bureaucratic decision which makes the common man suffer. “On one end they have their own myths about Oral Morphine and at other end these kind of least expensive Dextrpropoxyphene is being removed from market. We the palliative care community really needs to act on this”- said Dr. K. B. Linge Gowda, Head of the Department of Palliative Medicine, Kidwai Memorial Institute of Oncology, Bangalore.

“Today when we talk about inadequate access to pain treatment as a violation of basic human right , the ban of a drug like Dextroproxyphene will have a major impact on those hundreds of hapless patients who are in severe pain and don't have access to even basic pain medicines”- points out Dr. Gayathri Palat, MNJIO& RCC, Hyderabad. “This is a drug which is easily avaialble even in the remote part of India and affordable. Without this we are not left with many choices. We have to witness the suffering of one patient in that remote village to understand the implication of what we are talking about."- she said. 

Dr. Gayathri asked for immediate action saying that  the drug Propoxyphene should be considered as a special drug which should be made available on a humanitarian ground with clear guidelines and strong note of caution. 

Palliative care organisations in India are planning to appeal to the Drugs Controller of India to take out the ban on Dextropropoxyphene.
 

 

Share article

Article tags

    See more articles in Policy

    Comments | 0 comments

    Hide
    There are currently no comments. To be the first to make a comment...


    Add comment

    Denotes required field

    Your Name

    Email

    Comment


    Recommended Jobs

    Recommended Events